Ari Robinson

Ari holds a Ph. D degree in Neurobiology from the Tel-Aviv university. His Ph. D thesis was in the field of cellular biology and focused on mitochondrial regulation by the Alzheimer’s disease associated protein Presenilin 1 (PS1). Before Ari joined IMBM, he was working for biotechnology start-up company (Delphar biopharma) in the fields of drug discovery and as a researcher at the Joseph Sagol Neuroscience Center (JSNC) at Sheba hospital. Ari joined IMBM in 2020 and he manages the three projects that IMBM is currently working on, in the field of Prostate cancer, Melanoma and Covid-19.

Scientific activity in 2021

During this year, Ari was involved in all aspects of the three projects that IMBM is currently working on. Strategic planning for each project, possible goals and feasibility study based on literature search and availability of relevant data, finding scientific collaborators, and establishing a relationship with them based on benefit to all parties involved. Ari managed the efforts to retrieve real world clinical data from several medical centers (i.e., Sheba medical center, Mayo clinic, Tubingen medical center, Barzilai medical center, Soroka medical center) and HMO’s (i.e., Mehuchedet, Clalit and Maccabi) including all aspects of the Helsinki applications and the legal agreements. In addition to the above mentioned, much of his time in 2021 was spent by Ari searching for and writing grant applications in cooperation with Prof. Agur, in particular:

    1. Israel Cancer Research Fund (ICRF) in collaboration with Dr. Terresa Amaral and Prof. Thomas Eigentler from Tubingen medical center, Germany.
    2. Israel Science foundation (ISF) precision medicine in collaboration with Dr. Zohar Dothan from Sheba medical center, Israel.
    3. Department of Defense (DoD) in collaboration with Dr. Alan Bryce from Mayo clinic’s Phoenix Arizona.
    4. Israel Cancer Association (ICA) in collaboration with Dr. Alex Jacobson from Soroka medical center, Israel.
    5. Cancer Research Institute (CRI) – Letter of intent

    Scientific activity in 2022

    This year, Ari will continue to work on the current projects.
    Covid-19 – Additional covid patient’s clinical data will be retrieved from Sheba and Barzilai medical centers in accordance with algorithm developers needs. If machine learning based algorithm of personal prediction of covid-19 patient’s deterioration dynamics will be sufficiently accurate to be clinically beneficial (i.e., sensitivity and specificity above 0.8), we will progress to prospective observatory clinical trial in collaboration with Dr. Gadi Segal and Dr. Edi Itelman from Sheba medical center. In any case, the algorithm development efforts will be summarized and published in a peer review scientific journal. In addition, we will continue with our efforts to develop dynamic mechanistic model for prediction of covid-19 patients base on insights gained from real-world data analysis. If both algorithms will show synergy (i.e., could be combined for one algorithm with better performance than the separate algorithms) they will be combined for optimal predictions accuracy.

    Prostate cancer- Data of HSPC patients will be retrieved from Sheba medical center. If PSA measurements will be not sufficient, we will apply for the above-mentioned HMOs for additional PSA data of past measurements of Sheba’s patients. Adjustment of the current PSA prediction algorithm will be made to the new patient’s data and algorithm performance will be re-evaluated. In addition, and provided we receive the grant we submitted to the DoD, we will start a new prostate cancer project which will try to develop PSA prediction algorithm for CRPC patients under four different current treatments. Data of these patients will be received from Mayo clinic, Phoenix Arizona.

    Melanoma- We will concentrate all efforts to complete Tubingen’s medical center melanoma patient’s dataset (Ca. 250 patients under immunotherapy treatments) with SLDs measurement of these patients. We will try to establish a collaboration with Dr. Andreas Brendlin to receive past SLD measurements that he made for these patients. If ICA grant will be excepted, we will hire German radiologist to measure Tubingen’s patients SLDs and local Israeli radiologist to measure Soroka’s patients SLDs (collaboration with Dr. Alex Jacobson). After completion of melanoma patient’s dataset, we will further develop Neta’s algorithm with additional covariates of past treatments and re-evaluate its accuracy on a large dataset.

    Publications

      1. Katsel P., Fam P., Tan W., Khan S., Gama-Sosa M., De-Gasperi R., Roussos P., Robinson A., Cooper I., Schnaider-Beeri M., Haroutunian V.Engagement of Vascular Early Response Genes Typifies Mild Cognitive Impairment. Alzheimer’s & Dementia. 2021;1–13.

      2. Noa Tejman-Yarden., Ari Robinson., Yaakov Davidov., Alexander Varvak., Fernando Reyes., Galia Rahav., Israel Nissan. (2019) Delftibactin-A, a Non Ribosomal Peptide with Broad Antimicrobial Activity. Frontiers in microbiology. 2019 Oct;10 (2377)

      3. Ari Robinson*., Irit Lubitz*., Dana Atrakchi-Baranes., Avital Licht-Murava., Pavel Katsel., Derek Leroith., Sigal Liraz-Zaltsman., Vahram Haroutunian., Michal Schnaider Beeri. (2019) Combination of insulin with a GLP1 agonist is associated with better memory and normal expression of insulin receptor pathway genes in a mouse model of Alzheimer’s Disease. J Mol Neurosci. 2019 Apr;67(4):504-510.

      4. Lezana JP, Dagan SY, Robinson A, Goldstein RS, Fainzilber M, Bronfman FC, Bronfman M. (2016) Axonal PPARγ promotes neuronal regeneration after injury. Dev Neurobiol. Jun; 76(6):688-701.

      5. Robinson A., Grosgen S., Mett J.,Zimmer V.C., Haupenthal V.J., Hundsdorfer B., Stahlmann C., Slobodskoy Y., Muller U.C, Hartmann T., Stein R. and Grimm M.O.W. (2014) Upregulation of PGC-1α expression by Alzheimer’s disease associated pathway: presenilin 1/amyloid precursor protein (APP)/intracellular domain of APP. Aging Cell. Apr; 13(2):263-72.

      6. Robinson A., Kloog Y., Stein R., Assaf Y. (2010) Motor deficits and neurofibromatosis type 1 (NF1) -associated MRI impairments in mouse model of NF1. NMR Biomed. 23(10): 1173-1180.

      7. Fuchs E., Ayali A., Robinson A., Hulata E., Ben Jacob E. (2007) Co-emergence of regularity and complexity during neural network development. Dev. Neurobiol. 67(13): 1802-1814.

      8. Ayali A., Fuchs E., Zilberstein Y., Robinson A., Shefi O., Hulata E., Baruchi I., Ben-Jacob E. (2004) Contextual regularity and complexity of neuronal activity: from stand-alone cultures to task-performing animals. Complexity.9(6): 25-32.